HUE046182T2 - Az antibiotikumos kezelés kozkázatának becslése elsõdlegesen nem fertõzõ betegségben szenvedõ betegekben a prokalcitonin szintjének meghatározásával - Google Patents
Az antibiotikumos kezelés kozkázatának becslése elsõdlegesen nem fertõzõ betegségben szenvedõ betegekben a prokalcitonin szintjének meghatározásávalInfo
- Publication number
- HUE046182T2 HUE046182T2 HUE10717531A HUE10717531A HUE046182T2 HU E046182 T2 HUE046182 T2 HU E046182T2 HU E10717531 A HUE10717531 A HU E10717531A HU E10717531 A HUE10717531 A HU E10717531A HU E046182 T2 HUE046182 T2 HU E046182T2
- Authority
- HU
- Hungary
- Prior art keywords
- procalcitonin
- determining
- level
- infectious disease
- risk assessment
- Prior art date
Links
- 208000031662 Noncommunicable disease Diseases 0.000 title 1
- 108010048233 Procalcitonin Proteins 0.000 title 1
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940088710 antibiotic agent Drugs 0.000 title 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 title 1
- 238000012502 risk assessment Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09157886 | 2009-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE046182T2 true HUE046182T2 (hu) | 2020-02-28 |
Family
ID=40886944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10717531A HUE046182T2 (hu) | 2009-04-14 | 2010-04-14 | Az antibiotikumos kezelés kozkázatának becslése elsõdlegesen nem fertõzõ betegségben szenvedõ betegekben a prokalcitonin szintjének meghatározásával |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9046532B2 (https=) |
| EP (1) | EP2419741B1 (https=) |
| JP (1) | JP5650718B2 (https=) |
| CN (2) | CN105334330A (https=) |
| CY (1) | CY1122202T1 (https=) |
| DK (1) | DK2419741T3 (https=) |
| ES (1) | ES2751105T3 (https=) |
| HK (1) | HK1221766A1 (https=) |
| HR (1) | HRP20191862T1 (https=) |
| HU (1) | HUE046182T2 (https=) |
| LT (1) | LT2419741T (https=) |
| PL (1) | PL2419741T3 (https=) |
| PT (1) | PT2419741T (https=) |
| SI (1) | SI2419741T1 (https=) |
| WO (1) | WO2010118855A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2836841B1 (en) * | 2012-04-12 | 2022-01-05 | B.R.A.H.M.S GmbH | Prognosis of adverse events in patients with suspected chronic heart failure |
| CN105528511A (zh) * | 2014-10-25 | 2016-04-27 | 潘一琦 | 一种远程诊疗对比式问诊方法及其系统 |
| CN107301319B (zh) * | 2017-06-26 | 2021-02-26 | 济南市儿童医院 | 儿科临床及科研中抗菌药物使用危险评估系统 |
| JP7444776B2 (ja) * | 2017-12-20 | 2024-03-06 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併存症を有する患者におけるプロカルシトニンに基づく抗生物質療法のガイダンス |
| EP3502706A1 (en) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314804A (en) * | 1992-03-24 | 1994-05-24 | Serim Research Corporation | Test for Helicobacter pylori |
| DE19600875C1 (de) * | 1996-01-12 | 1997-06-26 | Brahms Diagnostica Gmbh | Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse |
| ATE395364T1 (de) * | 1999-12-22 | 2008-05-15 | Dade Behring Marburg Gmbh | Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung |
| JP2005522669A (ja) * | 2001-08-20 | 2005-07-28 | バイオサイト インコーポレイテッド | 卒中および脳損傷の診断マーカーおよびその使用方法 |
| US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
| DE102005034174A1 (de) * | 2005-07-21 | 2007-02-08 | B.R.A.H.M.S Ag | Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen |
| FR2894675B1 (fr) * | 2005-12-14 | 2008-06-27 | Assist Publ Hopitaux De Paris | Distinction des meningites bacteriennes et virales |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| CN103123359B (zh) * | 2007-08-03 | 2015-07-29 | B.R.A.H.M.S有限公司 | 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用 |
-
2010
- 2010-04-14 JP JP2012505086A patent/JP5650718B2/ja active Active
- 2010-04-14 DK DK10717531T patent/DK2419741T3/da active
- 2010-04-14 PL PL10717531T patent/PL2419741T3/pl unknown
- 2010-04-14 HU HUE10717531A patent/HUE046182T2/hu unknown
- 2010-04-14 CN CN201510626744.9A patent/CN105334330A/zh active Pending
- 2010-04-14 CN CN201080016849.8A patent/CN102395888B/zh active Active
- 2010-04-14 SI SI201031945T patent/SI2419741T1/sl unknown
- 2010-04-14 WO PCT/EP2010/002279 patent/WO2010118855A1/en not_active Ceased
- 2010-04-14 ES ES10717531T patent/ES2751105T3/es active Active
- 2010-04-14 US US13/264,252 patent/US9046532B2/en active Active
- 2010-04-14 HR HRP20191862TT patent/HRP20191862T1/hr unknown
- 2010-04-14 EP EP10717531.7A patent/EP2419741B1/en not_active Revoked
- 2010-04-14 LT LT10717531T patent/LT2419741T/lt unknown
- 2010-04-14 PT PT107175317T patent/PT2419741T/pt unknown
-
2015
- 2015-03-30 US US14/672,801 patent/US9810699B2/en active Active
-
2016
- 2016-08-16 HK HK16109795.0A patent/HK1221766A1/zh unknown
-
2017
- 2017-11-06 US US15/804,282 patent/US20180052179A1/en not_active Abandoned
-
2019
- 2019-10-24 CY CY20191101107T patent/CY1122202T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1221766A1 (zh) | 2017-06-09 |
| WO2010118855A1 (en) | 2010-10-21 |
| HRP20191862T1 (hr) | 2019-12-27 |
| EP2419741A1 (en) | 2012-02-22 |
| CN102395888B (zh) | 2017-05-03 |
| PL2419741T3 (pl) | 2020-01-31 |
| JP2012523573A (ja) | 2012-10-04 |
| CY1122202T1 (el) | 2020-11-25 |
| LT2419741T (lt) | 2019-11-11 |
| EP2419741B1 (en) | 2019-07-31 |
| US9810699B2 (en) | 2017-11-07 |
| DK2419741T3 (da) | 2019-11-04 |
| JP5650718B2 (ja) | 2015-01-07 |
| US20180052179A1 (en) | 2018-02-22 |
| US20120100635A1 (en) | 2012-04-26 |
| US20150247871A1 (en) | 2015-09-03 |
| ES2751105T3 (es) | 2020-03-30 |
| US9046532B2 (en) | 2015-06-02 |
| SI2419741T1 (sl) | 2019-12-31 |
| PT2419741T (pt) | 2019-11-04 |
| CN105334330A (zh) | 2016-02-17 |
| CN102395888A (zh) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259475A (en) | Combined therapy for the treatment of diabetes | |
| IL217901B (en) | Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases | |
| IL195135A0 (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders | |
| IL264349B1 (en) | Regimens containing neratinib for the treatment of cancer | |
| LT2427193T (lt) | Pde7 inhibitoriaus panaudojimas judėjimo sutrikimų gydymui | |
| ZA201006752B (en) | Spiro-indole derivatives for the treatment of parasitic disease | |
| ZA201203808B (en) | Combination for the treatment of radiation-or chemotherapy-induced mucositis | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| EP2563395A4 (en) | TREATMENT WITH ANTI-S1P ANTIBODY OF PATIENTS WITH OCULAR DISEASES | |
| LT2419741T (lt) | Pacientų, sergančių pirmine neinfekcine liga, gydymo antibiotikais rizikos įvertinimas, nustatant prokalcitonino kiekį | |
| IL207247A0 (en) | Use of ranolazine for the treatment of cardiovascular disease | |
| IL219050A0 (en) | Pharmaceutical composition for the treatment of bladder disorders | |
| IL216717A0 (en) | USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES | |
| PT2455073E (pt) | Combinação de substâncias para o tratamento de doentes com hipercolesterolemia e doenças relacionadas | |
| EP2392338A4 (en) | PROPHYLACTIC OR THERAPEUTIC FOR DISEASES RELATED TO ABNORMAL BONE MATERIAL CHANGE | |
| ZA201306759B (en) | Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system | |
| FR2945931B1 (fr) | Prothese destinee aux pathologies du type hernie ou eventration | |
| IL228973A (en) | Oxymetazoline for the treatment of rectal disorders | |
| GB201014519D0 (en) | In vivo screened models for treatment of isoQC-related disorders | |
| ZA200808104B (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders | |
| PL388849A1 (pl) | Urządzenie do diagnostyki i leczenia chorób odbytu | |
| GB0908666D0 (en) | Treatment of proteostatic disease | |
| GB0920651D0 (en) | Molecular methods for the treatment of disease |